DVA logo

DAVITA INC

DVANYSE
πŸ† #720 by market capEarnings Oct 29 Β· PostUS Equity
$183.93β–² $2.23 (+1.23%)
πŸŒ™ After hours$175.00β–Ό 4.86%Regular close Β· extended-hours price shown
πŸ””
Track DVA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.2%
7dβ–² 4.1%
14dβ–² 1.8%
30dβ–² 3.3%
ytdβ–² 61.9%
1yβ–² 41.9%
🏦Market Cap
$11.73B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
6.5%
Slowing
πŸ“ŠGross Margin
32.4%
Moderate
πŸ’΅FCF Margin
11.5%
Healthy
βš–οΈP/S Ratio
0.8x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$181.00 – $184.53
52-Week Range
$101.00 – $247.49
Volume (shares)
439,066
Avg Volume (shares)
β€”
Shares Outstanding
63.8M
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$13.64B
Last Q Revenue
$3.55B
P/E Ratio
13.8
P/S Ratio
0.8x
EPS (TTM)
$12.21
Dividend Yield
β€”
Dilution (1yr)
+5.1%
DVA logo

DAVITA INC

DVA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$13.6Bβ–² +6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
27.0%β–Ό βˆ’17.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.0Bβ–Ό βˆ’3.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.3Bβ–Ό βˆ’10.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
88.1Mβ–² +5.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$14.3Bβ–Ό βˆ’$3.0B YoY
StockOtter Β· stockotter.space

About DAVITA INC

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·1d ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (β€œDaVita” or the β€œCompany”) (NYSE: DVA). Such investors are advised to contact Danielle Peyton atΒ ne

Zacks Investment ResearchΒ·1d ago

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?

DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.

PRNewsWireΒ·1d ago

DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks

Nearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don'

Zacks Investment ResearchΒ·5d ago

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know

DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.

Zacks Investment ResearchΒ·6d ago

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.

Defense WorldΒ·7d ago

DaVita Inc. $DVA Position Lifted by CWA Asset Management Group LLC

CWA Asset Management Group LLC grew its stake in DaVita Inc. (NYSE: DVA) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investo